PT-141 (Bremelanotide): Peptide for Libido and Sexual Function

PT-141, also known as bremelanotide, is a synthetic peptide analog of alpha-melanocyte stimulating hormone (alpha-MSH) that activates melanocortin receptors in the brain to enhance sexual desire and function. Unlike PDE5 inhibitors (Viagra, Cialis) that work peripherally by increasing blood flow to genital tissue, PT-141 works centrally — it directly activates the neural circuits governing sexual motivation. This central mechanism allows it to address low libido and sexual dysfunction at the source, including in individuals who have no vascular component to their dysfunction.

In 2019, the FDA approved bremelanotide (Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of very few peptides with an FDA-approved indication for sexual health.

Mechanism of Action

PT-141 is a cyclic heptapeptide derived from melanotan-II. It acts as an agonist at melanocortin receptor subtypes MC1R, MC3R, and MC4R. The MC4R in the hypothalamus is the critical mediator of its sexual effects.

MC4R activation in the hypothalamus:

• Increases dopamine release in the mesolimbic (reward) system, promoting motivation and desire
• Activates oxytocin neurons in the paraventricular nucleus, releasing oxytocin that contributes to arousal and social bonding
• Modulates descending neural signals to the spinal cord that govern genital arousal responses (erection in men; clitoral engorgement and vaginal lubrication in women)

This central mechanism explains why PT-141 can produce sexual arousal in the absence of physical stimulation — a property that distinguishes it from PDE5 inhibitors, which require physical arousal to initiate the NO/cGMP cascade that causes erection.

FDA Approval (Vyleesi)

Bremelanotide (Vyleesi) was FDA-approved in June 2019 for acquired, generalized HSDD in premenopausal women. The approval was based on two Phase 3 randomized controlled trials (RECONNECT studies):

RECONNECT trials: 1,247 premenopausal women with HSDD received bremelanotide 1.75 mg subcutaneously as-needed (up to once per day, taken 45 minutes before anticipated sexual activity) or placebo. Results:

• Significantly more women in the bremelanotide group reported meaningful improvement in sexual desire versus placebo (25% vs. 17%)
• Significant improvement in the Female Sexual Function Index (FSFI) desire subscale
• Reduction in distress associated with low sexual desire

While the effect size was modest, it was consistent and clinically meaningful for the target population.

Use in Men

PT-141 does not have FDA approval for male sexual dysfunction, but it is used off-label and anecdotally by men for erectile dysfunction, particularly cases that have a psychogenic or low-libido component rather than a purely vascular mechanism.

Studies in men show PT-141 produces significant erections — in a Phase 2a trial of men with erectile dysfunction, intranasal PT-141 (at doses of 4 and 7 mg) produced erections of sufficient rigidity for intercourse in 79% of responders at the higher dose. The erections occurred spontaneously (without visual stimulation), confirming the central mechanism.

Dosage and Administration

FDA-approved female dosing (Vyleesi):

• 1.75 mg subcutaneously 45 minutes before anticipated sexual activity
• No more than one dose per 24 hours; no more than one dose per 24-hour period
• Inject in the abdomen or thigh

Research/off-label dosing (men and women):

• 0.5–2 mg subcutaneously 30–60 minutes before activity
• Start with 0.5–1 mg to assess tolerance (nausea is the primary dose-limiting side effect)
• Some individuals find 0.5 mg effective with minimal side effects; others require 2 mg

Intranasal (less common in current practice):

• 4–7 mg intranasally (studied in Phase 2 trials but produced significant nausea at effective doses; the subcutaneous route is preferred for better tolerability)

Frequency: As-needed use. Not a daily dosing peptide. Daily or high-frequency use has not been studied for long-term safety.

Side Effects

Nausea (most common): Occurs in approximately 40% of users in the FDA trials. Usually begins 30–60 minutes post-injection and resolves within 1–2 hours. Dose-dependent; lowest effective dose minimizes nausea.

Flushing: Transient warmth, redness, and tingling sensation. Very common (approximately 40%); usually brief.

Transient blood pressure increase: PT-141 can transiently increase blood pressure, which was the primary cardiovascular safety finding in trials. The FDA labels Vyleesi as contraindicated in individuals with cardiovascular disease or uncontrolled hypertension.

Hyperpigmentation: MC1R activation can increase melanin production with repeated use. Clinical trials show small areas of hyperpigmentation (face, gums, breasts) in some long-term users.

Headache: Reported in approximately 11% of Phase 3 participants.

Regulatory Status

Bremelanotide is FDA-approved as Vyleesi for premenopausal women with HSDD. It is a Schedule IV controlled substance designation has not been applied; it requires a prescription. Off-label use in men or for other indications requires physician prescription. PT-141 sold as a research peptide exists in a legal gray area in the US.

FAQ

How long do the effects of PT-141 last? The libido and arousal-enhancing effects typically last 6–12 hours after a single dose, with the peak effect occurring 1–2 hours post-injection. The erection-facilitating effect in men may persist for several hours.

Can PT-141 be used by postmenopausal women? The FDA approval specifically covers premenopausal women. Postmenopausal sexual dysfunction often has hormonal components (estrogen, testosterone decline) that are better addressed with hormone replacement. PT-141 may still have central effects in postmenopausal women, but this has not been the focus of clinical trials.

Does PT-141 work for psychological ED? The central mechanism of PT-141 — driving sexual motivation and arousal through dopaminergic and oxytocinergic pathways — is theoretically well-suited to psychogenic ED where the vascular mechanism is intact but desire and arousal are impaired. Many men report positive responses in this context.

Related Articles

• Afamelanotide: FDA-Approved Melanocyte Peptide
• AOD-9604: HGH Fragment for Fat Loss
• Argireline: The Topical Peptide Alternative to Botox?
• Bacteriostatic Water for Peptides: Why It Matters and How to Use It
• Best Peptide Stacks for Recovery, Fat Loss, and Longevity

Track your supplements in Optimize.